天茂集团(000627) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter reached ¥12,565,191,853.09, representing a year-on-year increase of 63.71%[3] - The net profit attributable to shareholders decreased by 31.73% to ¥37,692,725.67 compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥39,751,674.67, down 29.90% year-on-year[3] - Net profit for the current period was ¥649,378,911.12, a decline from ¥1,109,221,128.54 in the previous period, reflecting a decrease of approximately 41.4%[19] - The net profit attributable to the parent company was CNY 352,506,704.21, a decrease from CNY 575,626,703.86 in the previous period, representing a decline of approximately 38.9%[20] - The total comprehensive income amounted to CNY 2,504,005,118.40, significantly up from CNY 114,811,593.32 in the previous period[20] - The basic and diluted earnings per share were both CNY 0.0713, down from CNY 0.1165 in the previous period, indicating a decrease of about 38.8%[20] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥254,706,491,290.07, an increase of 6.39% from the end of the previous year[3] - Total assets increased to ¥254,706,491,290.07 from ¥239,402,637,169.94, marking a growth of about 6.5%[16] - Total liabilities rose to ¥217,563,857,950.17, up from ¥204,814,717,027.69, which is an increase of approximately 6.5%[16] - Non-current assets totaled ¥207,049,969,480.64, compared to ¥187,659,586,057.27 in the previous period, showing an increase of about 10.3%[16] - The company’s total liabilities include CNY 40,899,674,764.93 in policyholder savings and investment funds[28] Cash Flow - The net cash flow from operating activities was negative at -¥2,203,186,675.27, a decline of 113.00% year-on-year[7] - Cash flow from operating activities showed a net outflow of CNY -2,203,186,675.27, compared to a net inflow of CNY 16,950,190,783.68 in the previous period[23] - Cash inflow from investment activities totaled CNY 68,315,447,906.06, an increase from CNY 57,278,908,041.86 in the previous period[23] - The net cash flow from financing activities was CNY 7,763,992,441.06, a significant improvement from a net outflow of CNY -4,827,141,217.99 in the previous period[24] - The total cash and cash equivalents at the end of the period were CNY 21,930,290,560.91, down from CNY 22,962,626,092.25 in the previous period[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 78,394[8] - The largest shareholder, New Liyi Group Co., Ltd., holds 44.56% of shares, totaling 2,201,658,177 shares[8] - The second-largest shareholder, Wang Wei, owns 11.25% of shares, amounting to 555,604,700 shares[8] - The total number of shares held by the top ten unrestricted shareholders is 3,267,000,000 shares[10] - The company has no known related party relationships among the top ten shareholders[10] Operational Highlights - The company reported a significant increase in the issuance of bonds, with the amount reaching ¥5,210,000,000.00, up 112.65% from the previous year[5] - The company plans to focus on expanding its market presence and enhancing its product offerings in the upcoming quarters, although specific new products or technologies were not detailed in the call[19] Current and Non-Current Assets - The company's total current assets as of September 30, 2021, are approximately ¥47.66 billion, a decrease from ¥51.74 billion at the end of 2020[13] - Total current assets amounted to CNY 51,743,051,112.67, unchanged from the previous period[27] - Total non-current assets increased by CNY 66,855,424.28 to CNY 187,726,441,481.55[27] - The total non-current assets include available-for-sale financial assets valued at approximately ¥114.42 billion, up from ¥104.83 billion[13] Government Support - The company received government subsidies amounting to ¥4,095,114.13 during the reporting period[4] Tax and Other Comprehensive Income - The company reported a tax effect of CNY 1,854,626,207.28 in other comprehensive income, contrasting with a loss of CNY -994,409,535.22 in the previous period[20] Audit Status - The third quarter report was not audited[29]

Biocause Pharma-天茂集团(000627) - 2021 Q3 - 季度财报 - Reportify